Previous study reported loss of hsa-miR-128 as one mechanism through which breast tumor–initiating cells (BT-IC) can resist doxorubicin, through regulation of Bmi-1 and ABCC5 multidrug resistance protein26. Here, ABCC5 is linked to breast neoplasm.